Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases?

References

• Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020 Mar 19;91(1):157–160.
   PubMedGoogle Scholar
• Organization WH. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update [Internet]. World Health Organization; 2020 [cited 2021 Mar 12]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
   Google Scholar
• Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug;584(7821):430–436. .
   PubMed Web of Science ®Google Scholar
• Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington State. Jama. 2020 Apr 28;323(16):1612–1614.
   PubMed Web of Science ®Google Scholar
• Robinson JL, Lee EB, Xie SX, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018 Jul 1;141(7):2181–2193.
   PubMedGoogle Scholar
• Atkins JL, Masoli JAH, Delgado J, et al. Preexisting comorbidities predicting COVID-19 and Mortality in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2224–2230.
   PubMed Web of Science ®Google Scholar
• Vignatelli L, Zenesini C, Belotti LMB, et al. Risk of hospitalization and death for COVID-19 in people with parkinson’s disease or parkinsonism. Mov Disord. 2021 Jan;36(1):1–10. .
   PubMed Web of Science ®Google Scholar
• Ferini-Strambi L, Salsone M. COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable? J Neurol. 2020 Jul;21:1–11.
   Google Scholar
• Bianchetti A, Rozzini R, Guerini F, et al. Clinical presentation of COVID19 in dementia patients. J Nutr Health Aging. 2020;24(6):560–562. .
   PubMed Web of Science ®Google Scholar
• Covino M, De Matteis G, Santoro M, et al. Clinical characteristics and prognostic factors in COVID-19 patients aged ≥80 years. Geriatr Gerontol Int. 2020 Jul;20(7):704–708. .
   PubMed Web of Science ®Google Scholar
• Zheng C, Kar I, Chen CK, et al. Multiple sclerosis disease-modifying therapy and the COVID-19 pandemic: implications on the risk of infection and future vaccination. CNS Drugs. 2020 Sep;34(9):879–896. .
   PubMed Web of Science ®Google Scholar
• Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020 Sep 1;77(9):1079–1088.
   PubMed Web of Science ®Google Scholar
• Abiodun OA, Ola MS. Role of brain renin angiotensin system in neurodegeneration: an update. Saudi J Biol Sci. 2020 Mar;27(3):905–912.
   PubMed Web of Science ®Google Scholar
• Dolatshahi M, Sabahi M, Aarabi MH. Pathophysiological clues to how the emergent SARS-CoV-2 can potentially increase the susceptibility to neurodegeneration. Mol Neurobiol. 2021 Jan;8:1–16.
   Google Scholar
• Kehoe PG, Wong S, Al Mulhim N, et al. Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology. Alzheimers Res Ther. 2016 Nov 25;8(1):50.
   PubMedGoogle Scholar
• Zubenko GS, Volicer L, Direnfeld LK, et al. Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer’s disease, Parkinson’s disease and progressive supranuclear palsy. Brain Res. 1985 Mar 4;328(2):215–221.
   PubMed Web of Science ®Google Scholar
• Kawajiri M, Mogi M, Higaki N, et al. Angiotensin-converting enzyme (ACE) and ACE2 levels in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler. 2009 Feb;15(2):262–265. .
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV–2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 Apr 16;181(2):271–280.e8. .
   PubMed Web of Science ®Google Scholar
• Li Z, Xu X, Yang M, et al. Role of angiotensin-converting enzyme 2 in neurodegenerative diseases during the COVID-19 pandemic. Aging (Albany NY). 2020 Nov 10;12(23):24453–24461. .
   PubMedGoogle Scholar
• Mahalaxmi I, Kaavya J, Mohana Devi S, et al. COVID-19 and olfactory dysfunction: a possible associative approach towards neurodegenerative diseases. J Cell Physiol. 2021 Feb;236(2):763–770. .
   PubMed Web of Science ®Google Scholar
• Willis MD, Robertson NP. Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2. J Neurol. 2020 May;267(5):1567–1569.
   PubMed Web of Science ®Google Scholar
• Mok VCT, Pendlebury S, Wong A, et al. Tackling challenges in care of Alzheimer’s disease and other dementias amid the COVID-19 pandemic, now and in the future. Alzheimers Dement. 2020 Nov;16(11):1571–1581. .
   PubMed Web of Science ®Google Scholar
• Boutoleau-Bretonnière C, Pouclet-Courtemanche H, Gillet A, et al. The effects of confinement on neuropsychiatric symptoms in alzheimer’s disease during the COVID-19 crisis. J Alzheimers Dis. 2020;76(1):41–47. .
   PubMed Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020 Mar;579(7798):265–269. .
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270–273. .
   PubMed Web of Science ®Google Scholar
• Organization WH. Draft landscape of COVID-19 candidate vaccines [Internet]. World Health Organization; 2020 [cited 2021 Mar 12]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
   Google Scholar
• Delrue I, Verzele D, Madder A, et al. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges. Expert Rev Vaccines. 2012 Jun;11(6):695–719. .
   PubMed Web of Science ®Google Scholar
• Rajão DS, Chen H, Perez DR, et al. Vaccine-associated enhanced respiratory disease is influenced by haemagglutinin and neuraminidase in whole inactivated influenza virus vaccines. J Gen Virol. 2016 Jul;97(7):1489–1499. .
   PubMedGoogle Scholar
• Haynes BF, Corey L, Fernandes P, et al. Prospects for a safe COVID-19 vaccine. Sci Transl Med. 2020 Nov 4;12(568):eabe0948.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020 Nov 17;21(2):181–192.
   PubMed Web of Science ®Google Scholar
• Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020 Oct;586(7830):516–527.
   PubMed Web of Science ®Google Scholar
• Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004 Dec 18-31;364(9452):2181–2187.
   PubMed Web of Science ®Google Scholar
• Halperin SA, Das R, Onorato MT, et al. Immunogenicity, lot consistency, and extended safety of rVSVΔG-ZEBOV-GP vaccine: a phase 3 randomized, double-blind, placebo-controlled study in healthy adults. J Infect Dis. 2019 Aug 30;220(7):1127–1135.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99–111.
   PubMed Web of Science ®Google Scholar
• Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021 Jan 9;397(10269):72–74.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 Feb 4;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Keech C, Albert G, Cho I, et al. Phase 1-2 Trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020 Dec 10;383(24):2320–2332.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021 Jan;21(1):39–51.
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 2;352(22):2271–2284.
   PubMed Web of Science ®Google Scholar
• Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006 Feb 20;24(8):1159–1169.
   PubMed Web of Science ®Google Scholar
• Nipper AJ, Smithey MJ, Shah RC, et al. Diminished antibody response to influenza vaccination is characterized by expansion of an age-associated B-cell population with low PAX5. Clin Immunol. 2018 Aug;193:80–87.
   PubMed Web of Science ®Google Scholar
• Kiecolt-Glaser JK, Glaser R, Gravenstein S, et al. Chronic stress alters the immune response to influenza virus vaccine in older adults. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3043–3047.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck R, Falsey AR, et al. RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study. medRxiv. 2020 Aug;20. DOI:10.1101/2020.08.17.20176651
   Google Scholar
• Ristori G, Buzzi MG, Sabatini U, et al. Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis. Neurology. 1999 Oct 22;53(7):1588.
   PubMed Web of Science ®Google Scholar
• Ahlgren C, Torén K, Odén A, et al. A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. Eur J Epidemiol. 2009;24(9):541–552. .
   PubMed Web of Science ®Google Scholar
• Griffin MR, Ray WA, Mortimer EA, et al. Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine. Jama. 1990 Mar 23-30;263(12):1641–1645.
   PubMed Web of Science ®Google Scholar
• Arnheim-Dahlström L, Hällgren J, Weibull CE, et al. Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study. Bmj. 2012 Dec;345(3):e7594. .
   PubMedGoogle Scholar
• Håberg SE, Aaberg KM, Surén P, et al. Epilepsy in children after pandemic influenza vaccination. Pediatrics. 2018 Mar;141(3):e20170752. .
   PubMed Web of Science ®Google Scholar
• Verbeek NE, Van Der Maas NA, Sonsma AC, et al. Effect of vaccinations on seizure risk and disease course in Dravet syndrome. Neurology. 2015 Aug 18;85(7):596–603.
   PubMed Web of Science ®Google Scholar
• Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. Jama. 2004 Jul 21;292(3):351–357.
   PubMed Web of Science ®Google Scholar
• Jevtic S, Sengar AS, Salter MW, et al. The role of the immune system in Alzheimer disease: etiology and treatment. Ageing Res Rev. 2017 Nov;40:84–94.
   PubMed Web of Science ®Google Scholar
• Quandelacy TM, Viboud C, Charu V, et al. Age- and sex-related risk factors for influenza-associated mortality in the United States between 1997-2007. Am J Epidemiol. 2014 Jan 15;179(2):156–167.
   PubMed Web of Science ®Google Scholar
• Kaji M, Tsuru T, Oizumi K. [Efficacy and safety of influenza vaccination to elderly patients with neurological diseases]. Kansenshogaku Zasshi. 2001 May;75(5):411–415.
   PubMedGoogle Scholar
• Yang Y, He Z, Xing Z, et al. Influenza vaccination in early Alzheimer’s disease rescues amyloidosis and ameliorates cognitive deficits in APP/PS1 mice by inhibiting regulatory T cells. J Neuroinflammation. 2020 Feb 19;17(1):65.
   PubMed Web of Science ®Google Scholar
• Gagliardi AM, Andriolo BN, Torloni MR, et al. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2019 Nov 7;2019(11). DOI:10.1002/14651858.CD008858.pub4.
   PubMedGoogle Scholar
• Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis. 2010 Jul 15;51(2):197–213.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May 28;372(22):2087–2096.
   PubMed Web of Science ®Google Scholar
• Drolet M, Zhou Z, Sauvageau C, et al. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study. Cmaj. 2019 Aug 26;191(34):E932–e939.
   PubMed Web of Science ®Google Scholar
• Eichner M, Schwehm M, Eichner L, et al. Direct and indirect effects of influenza vaccination. BMC Infect Dis. 2017 Apr 26;17(1):308.
   PubMed Web of Science ®Google Scholar
• Reichert TA, Sugaya N, Fedson DS, et al. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med. 2001 Mar 22;344(12):889–896.
   PubMed Web of Science ®Google Scholar
• Le Houézec D. Evolution of multiple sclerosis in France since the beginning of hepatitis B vaccination. Immunol Res. 2014 Dec;60(2–3):219–225.
   PubMed Web of Science ®Google Scholar
• Bardage C, Persson I, Ortqvist A, et al. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. Bmj. 2011 Oct;343(2):d5956.
   PubMedGoogle Scholar
• Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in multiple sclerosis study group. N Engl J Med. 2001 Feb 1;344(5):319–326.
   PubMed Web of Science ®Google Scholar
• Lebrun C, Vukusic S. Immunization and multiple sclerosis: recommendations from the french multiple sclerosis society. Rev Neurol (Paris). 2019 Jun;175(6):341–357.
   PubMed Web of Science ®Google Scholar
• Mailand MT, Frederiksen JL. Vaccines and multiple sclerosis: a systematic review. J Neurol. 2017 Jun;264(6):1035–1050.
   PubMed Web of Science ®Google Scholar
• Scheller NM, Svanström H, Pasternak B, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. Jama. 2015 Jan 6;313(1):54–61.
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Guillemot D, Godeau B, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014 Apr;275(4):398–408. .
   PubMed Web of Science ®Google Scholar
• Bansil S, Singhal BS, Ahuja GK, et al. Multiple sclerosis in India: a case-control study of environmental exposures. Acta Neurol Scand. 1997 Feb;95(2):90–95. .
   PubMed Web of Science ®Google Scholar
• Freedman MS, Selchen D, Prat A, et al. Managing multiple sclerosis: treatment initiation, modification, and sequencing. Can J Neurol Sci. 2018 Sep;45(5):489–503. .
   PubMed Web of Science ®Google Scholar
• Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 May 30;395(10238):1695–1704.
   PubMed Web of Science ®Google Scholar
• Olberg HK, Eide GE, Cox RJ, et al. Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. Eur J Neurol. 2018 Mar;25(3):527–534. .
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Freedman MS, Kremenchutzky M, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013 Aug 6;81(6):552–558.
   PubMed Web of Science ®Google Scholar
• Lalosević D, Lalosević V, Sarić M, et al. [Fatal outcome after postexposure rabies vaccination in a patient with Parkinson’s disease]. Med Pregl. 2004 Sep-Oct;57(9–10):487–492. .
   PubMedGoogle Scholar
• Schwid SR, Decker MD, Lopez-Bresnahan M. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology. 2005 Dec 27;65(12):1964–1966.
   PubMed Web of Science ®Google Scholar
• Mehling M, Fritz S, Hafner P, et al. Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy. PLoS One. 2013;8(11):e78532.
   PubMed Web of Science ®Google Scholar
• Olberg HK, Cox RJ, Nostbakken JK, et al. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Mult Scler. 2014 Jul;20(8):1074–1080.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Wiendl H, Miller B, et al. Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurol Neuroimmunol Neuroinflamm. 2015 Apr;2(2):e70. .
   PubMed Web of Science ®Google Scholar
• Metze C, Winkelmann A, Loebermann M, et al. Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies. CNS Neurosci Ther. 2019 Feb;25(2):245–254.
   PubMed Web of Science ®Google Scholar
• Kappos L, Mehling M, Arroyo R, et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology. 2015 Mar 3;84(9):872–879.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology. 2020 Oct 6;95(14):e1999–e2008.
   PubMed Web of Science ®Google Scholar
• Walzer P, Estève C, Barben J, et al. Impact of influenza vaccination on mortality in the oldest old: A propensity score-matched cohort study. Vaccines (Basel). 2020 Jul 3;8(3). DOI:10.3390/vaccines8030356.
   PubMed Web of Science ®Google Scholar
• Yeh CH, Lin SF, Lin CY, et al. Acute onset of parkinsonism with reversible course after H1N1 vaccination: insight from a young lady. J Neuropsychiatry Clin Neurosci. 2012;24(4):E34–5. Fall. .
   PubMed Web of Science ®Google Scholar
• Shaw CA, Tomljenovic L. Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity. Immunol Res. 2013 Jul;56(2–3):304–316.
   PubMed Web of Science ®Google Scholar
• Thinnes FP. Opening cell membrane-standing type-1 VDAC/porin channels by trivalent aluminium-a factor in amyotrophic lateral sclerosis and Alzheimer’s disease? Mol Genet Metab. 2010 Oct-Nov;101(2–3):299–300.
   PubMed Web of Science ®Google Scholar
• Shaw CA, Petrik MS. Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration. J Inorg Biochem. 2009 Nov;103(11):1555–1562.
   PubMed Web of Science ®Google Scholar
• Petrik MS, Wong MC, Tabata RC, et al. Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice. Neuromolecular Med. 2007;9(1):83–100. .
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials. Jama. 2020 Sep 8;324(10):951–960.
   PubMed Web of Science ®Google Scholar
• Miller D, Madge N, Diamond J, et al. Pertussis immunisation and serious acute neurological illnesses in children. Bmj. 1993 Nov 6;307(6913):1171–1176.
   PubMedGoogle Scholar
• Kulenkampff M, Schwartzman JS, Wilson J. Neurological complications of pertussis inoculation. Arch Dis Child. 1974 Jan;49(1):46–49.
   PubMed Web of Science ®Google Scholar
• Moore DL, Le Saux N, Scheifele D, et al. Lack of evidence of encephalopathy related to pertussis vaccine: active surveillance by IMPACT, Canada, 1993-2002. Pediatr Infect Dis J. 2004 Jun;23(6):568–571. .
   PubMed Web of Science ®Google Scholar
• Ray P, Hayward J, Michelson D, et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatr Infect Dis J. 2006 Sep;25(9):768–773. .
   PubMed Web of Science ®Google Scholar
• Golden GS. Pertussis vaccine and injury to the brain. J Pediatr. 1990 Jun;116(6):854–861.
   PubMed Web of Science ®Google Scholar
• Sun Y, Christensen J, Hviid A, et al. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B. Jama. 2012 Feb 22;307(8):823–831.
   PubMed Web of Science ®Google Scholar
• Pruna D, Balestri P, Zamponi N, et al. Epilepsy and vaccinations: italian guidelines. Epilepsia. 2013 Oct;54(Suppl 7):13–22.
   PubMed Web of Science ®Google Scholar
• Berkovic SF, Harkin L, McMahon JM, et al. De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. Lancet Neurol. 2006 Jun;5(6):488–492.
   PubMed Web of Science ®Google Scholar
• McIntosh AM, McMahon J, Dibbens LM, et al. Effects of vaccination on onset and outcome of Dravet syndrome: a retrospective study. Lancet Neurol. 2010 Jun;9(6):592–598.
   PubMed Web of Science ®Google Scholar